Core Insights - Entera Bio Ltd. is developing EB613, the first once-daily oral anabolic PTH(1-34) tablet for postmenopausal women with osteoporosis at high risk for fracture [1][4] - The Phase 2 study showed significant increases in bone mineral density (BMD) at various skeletal sites compared to placebo, indicating a dual effect of stimulating bone formation and inhibiting resorption [1][2] - The company plans to initiate a Phase 3 registrational study for EB613 following positive Phase 2 results [5] Company Overview - Entera Bio is a clinical-stage company focused on oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology [5] - The company's pipeline includes five differentiated oral peptide programs targeting conditions such as osteoporosis, hypoparathyroidism, and obesity [5] - EB613 is positioned as a solution for the treatment gap in osteoporosis care, aiming to provide a simple daily tablet for patients who currently lack effective treatment options [4][5] Clinical Study Findings - The Phase 2 study randomized 161 postmenopausal women and demonstrated early effects on trabecular and cortical bone, suggesting rapid bone strengthening and fracture resistance [2][3] - 3D-DXA analysis revealed substantial improvements in areal BMD at the total hip and femoral neck, consistent with results from subcutaneous teriparatide [3] - The study's findings indicate a broad distribution of bone loss with placebo and a similar distribution of bone gain with EB613 in the femur [2] Market Context - Osteoporosis affects approximately 200 million women globally, with a significant risk of fragility fractures, particularly in postmenopausal women [4] - Current injectable anabolic treatments are not viable for many patients, highlighting the need for an effective oral treatment like EB613 [4]

Core Insights - Entera Bio Ltd. announced positive results from a Phase 2 study of EB613, an oral PTH(1-34) tablet aimed at treating postmenopausal women with osteoporosis at high risk for fractures [1][2][4] - The study demonstrated significant increases in bone mineral density (BMD) across various skeletal sites compared to placebo, indicating the potential for rapid bone strengthening and fracture resistance [2][3] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform [5] - The company's lead product, EB613, is positioned as the first oral anabolic treatment for postmenopausal women with low BMD and high-risk osteoporosis [5] - Entera is preparing to initiate a Phase 3 registrational study for EB613 following FDA qualification of a quantitative BMD endpoint [5] Study Details - The Phase 2 study involved 161 postmenopausal women and assessed the effects of EB613 over 6 months, showing improvements in integral volumetric BMD, trabecular volumetric BMD, cortical thickness, and cortical surface BMD compared to placebo [2][3] - 3D-DXA analysis indicated a dual effect of EB613, stimulating bone formation while inhibiting resorption, with significant improvements noted in both trabecular and cortical bone [1][2] Market Context - Osteoporosis is a significant health concern, affecting approximately 200 million women globally, with a high risk of fragility fractures [4] - Current injectable anabolic treatments are not viable for many patients, highlighting the need for an effective oral treatment option like EB613 [4]

Core Insights - Labcorp Holdings, Inc. has launched an FDA-approved HPV self-collection solution and a vaginal swab self-collect option for STI testing, aimed at improving cervical cancer screening rates and empowering individuals in managing their health [1][7]. Company Developments - The new self-collection solutions require a physician's order and can be completed privately at healthcare settings or Labcorp's 2,200 Patient Service Centers nationwide [2]. - Following the announcement, Labcorp's stock experienced a slight decline of 0.04%, closing at $232.65, but the company is addressing barriers to health screenings, which may positively influence market sentiment [3]. - Labcorp has a market capitalization of $19.48 billion, with earnings expected to grow by 9.9% and revenues by 7.1% according to the Zacks Consensus Estimate [4]. Industry Context - The U.S. has over 13,000 annual cervical cancer diagnoses, with approximately 4,000 fatalities, highlighting the importance of HPV testing for early intervention [5]. - The FDA approved self-collection tests for cervical cancer screenings in 2024, providing a less invasive alternative to traditional methods, which may improve screening rates [6]. - The global self-testing market was valued at $11.39 billion in 2024 and is projected to grow at a compound annual growth rate of 8.4% through 2030, driven by personalized healthcare and technological advancements [8]. Strategic Moves - Labcorp announced an agreement to acquire select assets of BioReference Health, focusing on oncology-related clinical testing services across the U.S. [10]. - In the past six months, Labcorp shares have increased by 8.2%, outperforming the industry average rise of 4.8% [11].

OPKO Health, Inc. Conference Call Summary Company Overview - OPKO Health, Inc. is involved in various projects including diagnostics, licensing agreements, and drug development, particularly in response to pandemic needs [4][6] Key Business Segments Pharmaceutical Division - **Rayaldee**: The only commercial product, sales growth impacted by the pandemic, with optimism for recovery as practices reopen [6] - **Label Expansions**: Plans for trials related to haemodialysis and COVID-19, with enrollment challenges due to vaccination progress [6][7] - **Growth Hormone**: PDUFA date in October for the U.S., with potential significant milestones upon approval and profit-sharing with Pfizer [7][8] Diagnostics Division - **BioReference Laboratories**: A full-service lab with expertise in women's health, oncology, and genetics, significantly increased COVID-19 testing capacity [9][10] - **COVID-19 Testing**: Conducted nearly 16 million tests, with a shift from testing for disease to surveillance testing [21][22] - **Digital Solutions**: Introduction of Scarlet, a home digital solution for lab tests, enhancing convenience and service delivery [17][18] GeneDx - Focused on rare pediatric diseases, showing strong performance post-pandemic with increased demand for genetic testing [11][14] - Partnership with Mednax to enhance NICU testing capabilities, aiming for early diagnosis of genetic abnormalities [14][47] Financial Performance - As of March 31, OPKO had approximately $90 million in cash and $165 million available on credit lines, with four consecutive quarters of operating profit due to COVID testing [12][26] - Guidance for Q2 includes 3 to 4 million COVID tests, projecting revenue between $385 million and $450 million [26] Market Dynamics - The base business is currently about 7% off pre-COVID levels, with expectations for gradual recovery as more people return to offices [17] - Continued interest in large-scale testing for schools and sports franchises, with ongoing discussions for contract renewals [21][24] Future Catalysts - Anticipated launch of Scarlet in more markets, with significant announcements expected in the coming weeks [46] - Potential for GeneDx to expand testing capabilities for a larger population of infants with undiagnosed genetic conditions [47][48] Regulatory and Competitive Landscape - Pfizer controls pricing for the growth hormone, with expectations for a rapid market switch to long-acting formulations [33][40] - Ongoing interactions with regulators as part of the approval process for new products [41] Conclusion - OPKO Health is positioned for growth with a strong focus on digital solutions, expanding diagnostic capabilities, and potential milestones in pharmaceutical products, particularly in the growth hormone market and pediatric genetic testing [48][49]

OPKO Health, Inc. (NASDAQ:OPK) Jefferies 2020 Virtual London Healthcare Conference November 18, 2020 10:15 AM ET Company Participants Jon Cohen - Senior Vice President, OPKO Health; Executive Chairman, BioReference Laboratories Adam Logal - Senior Vice President and Chief Financial Officer Steve Rubin - Executive Vice President, Administration Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft and I am one of the Biotech analysts at Jefferies. Tha ...